• S&P 500: 1,341.40
  • Change: -0.78%
$17.42 -0.30 (-1.69%)
2/10/2012 12:30 PM

Emergent BioSolutions, Inc. (NYSE:EBS)

CAPS Rating: 5 out of 5

A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.

Current Price $17.42 Mkt Cap $624.52M
Open $17.51 P/E Ratio 18.80
Prev. Close $17.72 Div. (Yield) N/A (N/A)
Daily Range $17.35 - $17.60 Volume 16,988
52-Wk Range $14.90 - $26.41 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think EBS will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

498 Outperform
18 Underperform
 

All-Star Players

132 Outperform
4 Underperform
 

Wall Street

5 Outperform
1 Underperform
 

Top EBS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

EnigmaDude (98.91)
Submitted October 03, 2011

Emergent BioSolutions receives award to supply 44.75 mln doses of BioThrax to U.S. Government over 5 Years for a total value of up to $1.25 bln

Add Comment | Reply | Report this Post

fewl10 (29.32)
Submitted December 15, 2008

Good grief. What a bubble

Add Comment | Reply | Report this Post
EBS VS S&P 500 (SPY)

Fools bullish on EBS are also bullish on:

Fools bearish on EBS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EBS.

Recs

2
Member Avatar EnigmaDude (98.91) Submitted: 10/3/2011 4:51:08 PM : Outperform Start Price: $16.89 EBS Score: -20.61

Emergent BioSolutions receives award to supply 44.75 mln doses of BioThrax to U.S. Government over 5 Years for a total value of up to $1.25 bln

Report this Post Add Comment | Reply | Permalink

Recs

2
Member Avatar zzlangerhans (99.31) Submitted: 7/30/2011 12:50:39 AM : Outperform Start Price: $20.51 EBS Score: -18.52

The stock has bounced upward from these levels twice already this year. The company claims that a dramatic drop in Biothrax revenues last quarter was due to an "internal process of redeployment" that has now been substantially completed. No, I don't know what that means. But they projected record revenues of 80-90M for the current quarter and total 2011 revenues of 320-340M, with net income of 35-45M. The next earnings will be reported on August 4 and if the company is true to their word, the share price will surely gap up. If they're surprised and disappointed, who knows.

Meanwhile the company has numerous other dishes in the kitchen. They recently initiated a phase Ib trial of cheaply acquired Trubion compound TRU-16 in relapsed B cell lymphoma. Trubion's SBI-087 is in a phase II dose finding study for rheumatoid arthritis. Data from a phase II trial of their TB vaccine in infants is expected in H2 2012, and a phase IIb trial of the TB vaccine in HIV patients may be initiated in the near future. The company has also acquired rights to zanolimumab anti-T cell antibody for CTCL and PTCL from TenX Biopharma.

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar TrojanFan (78.22) Submitted: 7/7/2011 4:13:41 PM : Outperform Start Price: $21.89 EBS Score: -20.61

Recent approval of Biothraxx by Singapore HSA is a promising development as the company tries to expand its marketing reach into other places such as Brunei.

I'm a little nervous about the impact of the debt ceiling debate and the potential for delayed or reduced purchases by the US govt, but given the homeland security angle that should offer them some protection.

I'm looking for good earnings for last quarter because their press releases indicate that they shipped a LOT of product this quarter.

Report this Post Add Comment | Reply | Permalink
View All 49 Pitches »

Leaderboard

Find the members with the highest scoring picks in EBS.

Score Leader

mattcguy

mattcguy (77.89) Score: +337.40

The Score Leader is the player with the highest score across all their picks in EBS.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Sandman333 63.34 11/15/2007 Outperform 5Y $4.70 +271.28% -3.66% +274.94 0 Comment
stewartsjunk < 20 12/18/2007 Outperform 5Y $4.81 +262.79% -3.71% +266.50 0 Comment
DBerriman < 20 11/27/2007 Outperform 3W $4.79 +264.30% -1.07% +265.37 1 Comment
CantSitStill 87.63 11/29/2007 Outperform 3Y $4.99 +249.70% -4.42% +254.12 0 Comment
jessba15 60.41 11/28/2007 Outperform 1Y $5.00 +249.00% -2.44% +251.44 0 Comment
orsibros < 20 11/28/2007 Outperform 5Y $5.00 +249.00% -2.44% +251.44 0 Comment
TRIPODTODD 51.84 12/4/2007 Outperform 3W $5.17 +237.52% -4.17% +241.69 0 Comment
caslonsvcs 95.62 12/27/2007 1/14/2012 Outperform 3M $5.25 +232.38% -5.71% +238.09 0 Comment
tenmiles 99.96 11/14/2007 Outperform 3Y $5.71 +205.60% -5.35% +210.96 3 Comments
no12call 42.72 1/7/2008 Outperform 3M $6.60 +164.39% -1.38% +165.78 0 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
trackwbbsecuriti 39.17 7/14/2010 Outperform NS $17.14 +1.81% +22.83% -21.03 0 Comment
TrackWedbush 86.49 3/20/2009 Outperform NS $12.44 +40.27% +74.76% -34.49 0 Comment
TrackCarisandCo 88.65 3/6/2009 Outperform NS $17.76 -1.75% +96.90% -98.65 0 Comment
TrackJimCramer 78.10 12/1/2008 Underperform 3W $22.37 -21.99% +67.77% +89.77 0 Comment
TrackCarisandCo 88.65 10/14/2008 Outperform NS $13.89 +74.30% -23.27% +97.56 2/17/2009 @ $24.21 0 Comment
TrackHSBC < 20 1/3/2007 Outperform NS $11.40 +53.07% +0.19% +52.88 0 Comment
TrackCowenandCo 84.16 1/3/2007 Outperform NS $11.40 +53.07% +0.19% +52.88 0 Comment

Featured Broker Partners